Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorasidenib - Servier

Next Previous
Drug Profile

Vorasidenib - Servier

Alternative Names: AG-881; AG-881 citrate; AGI-23088; S-95032; S095032; Vorasidenib citrate

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Servier
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Diamines; Fluorocarbons; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Glioma
  • Phase I Astrocytoma; Liver disorders
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 21 Feb 2024 Preregistration for Glioma (First-line therapy, In adolescents, In children, In the elderly, Recurrent, In adults) in European Union (PO)
  • 21 Feb 2024 Preregistration for Glioma (First-line therapy, In adolescents, In children, In the elderly, Recurrent, In adults) in USA (PO)
  • 20 Feb 2024 FDA assigns PDUFA action date of 20/08/2024 for vorasidenib for Glioma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top